Compugen Rockets on $540M Bayer Immunotherapy Alliance
By Jennifer Boggs
Wednesday, August 7, 2013
Shares of Compugen Ltd. jumped 44.5 percent Monday on news of a potential $540 million deal with Bayer Healthcare to develop antibody drugs for cancer immunotherapy, marking the Israeli firm's first substantial revenue-sharing drug development collaboration.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.